For the quarter ending 2026-03-31, MRVI had -$50,968K decrease in cash & cash equivalents over the period. $4,228K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on extinguishment of debt | - | 0 | - | - |
| Deferred income taxes | - | -20 | - | - |
| Change in estimated fair value of contingent consideration | - | 0 | 0 | - |
| Goodwill impairment | - | - | 0 | 42,884 |
| Net loss | -6,377 | -63,015 | -45,057 | -122,690 |
| Amortization of deferred financing costs | - | 403 | 399 | 852 |
| Revaluation of liabilities under the tax receivable agreement | - | 0 | - | - |
| Depreciation | 4,900 | 5,933 | 5,975 | 11,650 |
| Acquisition related tax adjustment | - | 0 | 0 | 4,082 |
| Change in fair value of derivative instruments | - | - | 0 | 0 |
| Change in estimated fair value of contingent consideration | - | - | - | 140 |
| Amortization of intangible assets | 6,472 | 6,512 | 7,209 | 14,230 |
| Amortization of operating lease right-of-use assets | 1,606 | 2,288 | 2,259 | 4,416 |
| Stock-based compensation expense | 6,743 | 3,926 | 9,056 | 17,192 |
| Impairment | 605 | 84,597 | - | - |
| Other | -541 | 1,079 | -334 | -957 |
| Accounts receivable | 7,914 | 2,961 | -5,116 | -10,661 |
| Inventory | -33 | -3,092 | -1,350 | -3,557 |
| Prepaid expenses and other current assets | -1,433 | -1,181 | -1,066 | 621 |
| Other assets | - | -181 | - | - |
| Deferred revenue | - | - | - | -735 |
| Accounts payable | 6,162 | -5,515 | -2,906 | 1,074 |
| Accrued expenses and other current liabilities | -5,336 | -13,514 | 1,514 | 7,374 |
| Other long-term liabilities | -203 | -1,893 | -2,060 | -14,678 |
| Net cash provided by (used in) operating activities | 8,665 | -22,768 | -15,150 | -19,655 |
| Cash paid for acquisitions of a business, net of cash acquired | 0 | 0 | 0 | 18,990 |
| Purchases of property and equipment | 4,437 | 2,114 | 2,926 | 8,109 |
| Proceeds from government assistance allocated to property and equipment | - | 0 | 0 | 734 |
| Payments of finance lease liabilities | - | - | 200 | 370 |
| Financing costs paid to acquire long-term debt | - | 0 | - | - |
| Purchase of technology | - | - | 0 | - |
| Other investing activities, net | - | 0 | - | - |
| Proceeds from interest rate cap agreement | - | 0 | 0 | 1,375 |
| Net cash used in investing activities | -4,437 | -2,114 | -2,926 | -26,365 |
| Payments of acquisition related contingent consideration and consideration holdback | - | 0 | 6,800 | - |
| Distributions for tax liabilities to non-controlling interest holder | - | - | 0 | 0 |
| Refunds (distributions) for tax liabilities to non-controlling interests holder | - | -10 | - | - |
| Payments pursuant to the tax receivable agreement | - | 0 | - | - |
| Principal repayments of long-term debt | 51,360 | 1,360 | 1,360 | 2,720 |
| Taxes paid for shares withheld under employee equity plans, net of proceeds from issuance of class a common stock | - | - | 111 | -4,719 |
| Other financing activities, net | -3,866 | -5,644 | - | - |
| Net cash used in financing activities | -55,226 | -1,816 | -8,249 | -6,434 |
| Effects of exchange rate changes on cash and cash equivalents | 30 | 14 | -8 | -38 |
| Net decrease in cash and cash equivalents | -50,968 | -26,684 | -26,333 | -52,492 |
| Cash and cash equivalents, beginning of period | 216,890 | 243,574 | 322,399 | - |
| Cash and cash equivalents, end of period | 165,922 | 216,890 | 243,574 | - |
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)